Investigational drug · Phase 3
KHN939
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "KHN939"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KHN939", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "KHN939" as an intervention, largest first.
- A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye DiseasePivotal-lookingNot yet recruiting
Beijing Kanghong Biological Medicine Co., Ltd.Industry
NCT07720648 · 117 participants (planned) · Start Aug 2026 · Primary completion May 2027
Drug: KHN939; Placebo · For: Thyroid Eye Disease
Sites: Shanghai, China
- A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye DiseasePivotal-lookingNot yet recruiting
Beijing Kanghong Biological Medicine Co., Ltd.Industry
NCT07720635 · 60 participants (planned) · Start Aug 2026 · Primary completion Apr 2027
Drug: KHN939; Placebo · For: Thyroid Eye Disease
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Thyroid Eye Disease
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
- lonigutamabPhase 21 trial
ACELYRIN Inc. · Thyroid Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.